XML 48 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Licensing, Acquisitions, and Other Arrangements - Acquisition of Allergan (Details) - USD ($)
$ / shares in Units, $ in Millions
2 Months Ended 3 Months Ended 6 Months Ended
May 08, 2020
Jun. 30, 2020
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Business Acquisition              
Closing price of AbbVie common stock (in dollars per share) $ 83.96            
Amortization of intangible assets     $ 1,400 $ 388 $ 1,850 $ 773  
Fair Value of Assets Acquired and Liabilities Assumed              
Goodwill   $ 42,669 42,669   42,669   $ 15,604
Allergan plc              
Business Acquisition              
Cash per share received by Allergan shareholders (in dollars per share) $ 120.30            
Amount of AbbVie stock per share received by Allergan shareholders (in shares) 0.8660            
Allergan ordinary shares outstanding at closing (in shares) 330,000,000            
Shares of AbbVie's common stock issued to Allergan shareholders (in shares) 286,000,000            
Stock options issued to Allergan's equity award holders (in shares) 11,200,000            
RSUs issued to Allergan's equity award holders (in shares) 8,200,000            
Fair value step-up adjustment to inventories $ 1,200            
Fair value step-up adjustment to inventories amortization period   1 year          
Weighted average useful life of acquired intangible assets   9 years          
Fair value of purchase price adjustment to long-term debt 1,300            
Net revenues attributable to Allergan from acquisition date   $ 2,000          
Operating losses attributable to Allergan from acquisition date   909          
Amortization of intangible assets   961          
Inventory fair value step-up amortization   $ 431          
Consideration Transferred              
Cash consideration paid to Allergan shareholders [1] 39,675            
Fair value of AbbVie common stock issued to Allergan shareholders [2] 23,979            
Fair value of AbbVie equity stock issued to Allergan equity award holders [3] 430            
Total consideration 64,084            
Fair Value of Assets Acquired and Liabilities Assumed              
Cash and equivalents 1,537            
Short-term investments 1,421            
Accounts receivable 2,423            
Inventories 2,370            
Prepaid expenses and other current assets 1,984            
Investments 137            
Property and equipment 1,912            
Intangible assets - Developed product rights 58,280            
Intangible assets - In-process research and development 1,040            
Other noncurrent assets 1,532            
Short-term borrowings (60)            
Current portion of long-term debt and finance lease obligations (1,899)            
Accounts payable and accrued liabilities (5,850)            
Long-term debt and finance lease obligations (18,937)            
Deferred income taxes (4,078)            
Other long-term liabilities (4,772)            
Total identifiable net assets 37,040            
Goodwill 27,044            
Total assets acquired and liabilities assumed $ 64,084            
Pro Forma Information              
Net revenues     11,542 12,267 23,761 23,657  
Net earnings (loss)     53 (1,735) 3,312 (3,726)  
Allergan plc | Selling, general and administrative              
Business Acquisition              
Acquisition-related expenses     $ 777 $ 24 $ 781 $ 24  
[1]
(a)
Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing.
[2]
(b)
Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for each outstanding Allergan ordinary share at the May 8, 2020 closing price of $83.96 per share.
[3]
(c)
Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.